AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 23 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A research team from the University of Antwerp in Belgium have developed a new and faster methods method of generating mature, viable, and highly active CD83+ dendritic cells.
"Dendritic cells are professional antigen-capturing and -presenting cells of the immune system," explained Peter Ponsaerts and his colleagues. "Because of their exceptional capability of activating tumor-specific T cells, cancer vaccination research is now shifting toward the formulation of a clinical human DC vaccine."
The investigators cultured human monocytes in serum-free AIM-V medium and allowed them to mature via polyriboinosinic polyribocytidylic acid (polyI:C) for 24 hours. The resulting DCs exhibited typical mature DC markers and high stimulatory potential. In an influenza model, peptide-pulsed DCs showed a large autologous stimulatory capacity (Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. Journal of Immunology, 2002;169(4):1669-1675).
Antigen loading was accomplished by electroporation of mRNA that encoded the enhanced green fluorescent protein (EGFP). After electroporation and a short period of serum-free maturation, the resulting cells showed typical mature DC characteristics and positive EGFP fluorescence. Autologous T cell activation studies demonstrated that ...
Source: HighBeam Research, New method shortens dendritic cell preparation time.